ACAD · Healthcare · $3.5B
$19.93-1.12%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“DAYBUE 매출 +30%, 이전 분기보다 뚜렷하게 가속됐어요 — 새로 나온 파우더 제형 STIX가 이탈했던 환자들까지 복귀시키면서 6월 한 달”
In the company's words · 2026 2분기 earnings call